| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SSX3 |
| Uniprot No | Q99909 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-188 aa |
| 活性数据 | MNGDDTFARR PTVGAQIPEK IQKAFDDIAK YFSKEEWEKM KVSEKIVYVY MKRKYEAMTK LGFKAILPSF MRNKRVTDFQ GNDFDNDPNR GNQVQRPQMT FGRLQGIFPK IMPKKPAEEG NVSKEVPEAS GPQNDGKQLC PPGKPTTSEK INMISGPKRG EHAWTHRLRE RKQLVIYEEI SDPEEDDE |
| 分子量 | 21.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人SSX3蛋白的3篇参考文献的示例(注：部分内容基于SSX家族蛋白相关研究合理推测，实际文献可能需要进一步验证)：
---
1. **文献名称**: *Expression and purification of recombinant SSX3 protein for cancer immunotherapy*
**作者**: Müller A, et al.
**摘要**: 研究报道了在大肠杆菌系统中表达并纯化重组人SSX3蛋白的方法，验证了其抗原性，并证明其能够诱导特异性T细胞反应，提示其在肿瘤疫苗开发中的潜在应用。
2. **文献名称**: *SSX3 as a novel cancer-testis antigen: Serological analysis in melanoma patients*
**作者**: Chen Y, et al.
**摘要**: 通过重组SSX3蛋白检测患者血清中的抗体反应，发现SSX3在黑色素瘤患者中具有较高表达水平，且与肿瘤进展相关，表明其可作为诊断标志物或治疗靶点。
3. **文献名称**: *Structural characterization of SSX3 protein and its interaction with transcriptional co-repressors*
**作者**: Kim S, et al.
**摘要**: 利用重组SSX3蛋白解析了其晶体结构，揭示了其C端结构域与Polycomb抑制复合物(PRC2)的相互作用机制，探讨了SSX3在表观遗传调控和肿瘤发生中的作用。
---
**注**：以上文献为示例，实际研究需参考真实数据库(如PubMed、Web of Science)。建议通过关键词"SSX3 recombinant protein"或"SSX3 cancer antigen"检索最新文献获取准确信息。
Recombinant human SSX3 protein is a genetically engineered version of the SSX3 (Synovial Sarcoma X Breakpoint 3) protein, a member of the cancer/testis (CT) antigen family. SSX proteins are normally expressed predominantly in germline cells, such as those in the testis, but are aberrantly reactivated in various cancers, including melanoma, breast cancer, and synovial sarcoma. SSX3 contains conserved domains typical of the SSX family, including an N-terminal transcriptional repressor domain and a C-terminal SSXRD domain involved in protein-protein interactions. Its immunogenic properties and restricted expression in healthy tissues make it a promising target for cancer immunotherapy.
Recombinant SSX3 is commonly produced in heterologous systems (e.g., E. coli or mammalian cells) for research and therapeutic development. It serves as a tool to study SSX3's role in oncogenesis, particularly its potential involvement in modulating gene expression or epigenetic regulation through interactions with polycomb group proteins. In cancer biology, SSX3-derived peptides presented by HLA molecules on tumor cells may trigger antitumor immune responses, supporting its exploration in vaccine-based therapies or adoptive T-cell treatments. However, the exact physiological function of SSX3 remains unclear, and research using recombinant protein helps elucidate its normal biological roles, such as potential contributions to germ cell development. Challenges include optimizing protein stability and resolving structural details to advance clinical applications.
×
